Efficacy of fibroblast growth factor 21 in non‐alcoholic fatty liver disease in guinea pigs

Differential Effects of Dietary Components on Glucose Intolerance and Non-Alcoholic Steatohepatitis

(2021) Josephine Skat-Rørdam et al.   Nutrients

Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease?

(2020) David H Ipsen et al.   Advances in Nutrition

BCPT policy for experimental and clinical studies

(2020) Pernille Tveden‐Nyborg et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Dietary Intervention Accelerates NASH Resolution Depending on Inflammatory Status with Minor Additive Effects on Hepatic Injury by Vitamin E Supplementation

(2020) Julie Hviid Klaebel et al.   Antioxidants

Atorvastatin and Vitamin E Accelerates NASH Resolution by Dietary Intervention in a Preclinical Guinea Pig Model

(2019) Julie Hviid Klaebel et al.   Nutrients

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2018) Stephen A Harrison et al.   LANCET

Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity

(2018) Archita Agrawal et al.   Molecular Metabolism

Differential receptor selectivity of the FGF15/FGF19 orthologues determines distinct metabolic activities in db/db mice

(2018) Ann Maria K. Hansen et al.   BIOCHEMICAL JOURNAL

Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis

(2018) Zobair Younossi et al.   HEPATOLOGY

FGF21 decreases food intake and body weight in obese Göttingen minipigs

(2018) Berit Christoffersen et al.   DIABETES OBESITY & METABOLISM

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

(2018) Arun Sanyal et al.   LANCET

FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in White and Brown Adipose Tissues

(2016) Christian Schlein et al.   Cell Metabolism

High-fat but not sucrose intake is essential for induction of dyslipidemia and non-alcoholic steatohepatitis in guinea pigs

(2016) David Højland Ipsen et al.   Nutrition & Metabolism

Normal weight dyslipidemia: Is it all about the liver?

(2016) David Højland Ipsen et al.   Obesity

Diet-induced dyslipidemia leads to nonalcoholic fatty liver disease and oxidative stress in guinea pigs

(2016) Pernille Tveden-Nyborg et al.   Translational Research

Distribution of vitamin C is tissue specific with early saturation of the brain and adrenal glands following differential oral dose regimens in guinea pigs

(2015) Stine Hasselholt et al.   BRITISH JOURNAL OF NUTRITION

Fibroblast growth factor 21 prevents glycemic deterioration in insulin deficient mouse models of diabetes

(2015) Birgitte Andersen et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Physiology and Endocrinology Symposium: FGF21: Insights into mechanism of action from preclinical studies1,2

(2014) P. J. Antonellis et al.   JOURNAL OF ANIMAL SCIENCE

The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes

(2013) Gregory Gaich et al.   Cell Metabolism

Long-Acting FGF21 Has Enhanced Efficacy in Diet-Induced Obese Mice and in Obese Rhesus Monkeys

(2012) Murielle M. Véniant et al.   ENDOCRINOLOGY

Lack of Overt FGF21 Resistance in Two Mouse Models of Obesity and Insulin Resistance

(2011) Clarence Hale et al.   ENDOCRINOLOGY

Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State

(2010) f. M. Fisher et al.   DIABETES

Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice

(2008) J. Xu et al.   DIABETES

Fibroblast Growth Factor 21 Corrects Obesity in Mice

(2008) Tamer Coskun et al.   ENDOCRINOLOGY